Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.

@article{Kolasa2016PotentialIO,
  title={Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.},
  author={Katarzyna Kolasa and Krzysztof Miroslaw Zwolinski and Zolt{\'a}n Kal{\'o} and Tomasz Roman Hermanowski},
  journal={Orphanet journal of rare diseases},
  year={2016},
  volume={11},
  pages={23}
}
BACKGROUND The objective of this study was to assess the potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement (P&R) process with regard to orphan drugs. METHODS A four step approach was designed. Firstly, a systematic literature review was conducted to select the MCDA criteria. Secondly, a database of orphan drugs was established. Thirdly, health technology appraisals (HTA recommendations) were categorized and an MCDA… CONTINUE READING
Highly Cited
This paper has 26 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

The promise of specialty pharmaceuticals: Are they worth the price

  • SD Sullivan
  • J Manag Care Pharm. 2008;14(suppl S):S3–6…
  • 2016
1 Excerpt

2014, Poland

  • OECD Health Statisti
  • http://www.oecd.org/els/healthsystems/Briefing…
  • 2015
1 Excerpt

Europe

  • EURORDIS Rare Disease
  • http://www.eurordis.org/content/moca. Accessed…
  • 2015
1 Excerpt

Transparent value framework (Platform on access to medicines in Europe - Working Group on Mechanism of coordinated access to orphan medicinal products), 19.11.2014

  • European Commission
  • http://ec.europa.eu/DocsRoom/ documents/7631…
  • 2015
1 Excerpt

Application of a policy framework for the public funding of drugs for rare diseases

  • E Winquist, D Coyle, JTR Clarke, GA Evans, C Seager, W. Chan
  • J Gen Intern Med
  • 2014

Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Diseases and Orphan Drugs

  • D Tordrup, V Tzouma, P. Kanavos
  • An Int J Public Health
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…